Skip to main content

Table 1 Efficacy of SARS CoV-2 Vaccines by Age Group in Phase III Clinical Trials

From: Depression, aging, and immunity: implications for COVID-19 vaccine immunogenicity

Vaccine Type Doses (interval) Median Follow-up Age Groups N
(vaccine vs placebo)
Efficacy
(95% CI)
Primary Efficacy Outcome Ref.
BioNTech/Pfizer
BNT162b2
mRNA 2 (3 weeks) 2 months All
16–55
> 55
18,198 vs 18,325
10,889 vs 10,896
7971 vs 7950
95.0 (90.0–97.9)
95.6 (89.4–98.5)
93.7 (80.6–98.8)
Confirmed CoVID-19 (symptoms in combination with PCR test) [46]
Moderna
mRNA-1273
mRNA 2 (4 weeks) 63 days All
18–64
> 64
14,134 vs 14,073
10,551 vs 10,521
3583 vs 3552
94.1 (89.3–96.8)
95.6 (90.6–97.9)
86.4 (61.4–95.2)
Symptomatic Covid-19 with onset at least 14 days after the second injection [47]
Janssen
Ad26.COV2-S
Viral vector 1 58 days All
18–59
> 59
21,895 vs 21,888
14,564 vs 14,547
7331 vs 7341
66.9 (59.0–73.4)
63.7 (53.9–71.6)
76.3 (61.6–89.0)
Moderate to severe–critical Covid-19 [48]
AstraZeneca/Oxford
ChAdOx1
Viral vector 2 (4–12 weeks) 61 days All
18–64
> 64
21,587 vs 10.792
16,760 vs 8381
4827 vs 2411
74.0 (65.3–80.5)
72.8 (63.4–79.9)
83.5 (54.2–94.1)
Symptomatic illness [49]